Microbiology Spectrum,
Год журнала:
2024,
Номер
12(3)
Опубликована: Фев. 6, 2024
ABSTRACT
It
is
urgently
needed
to
evaluate
the
necessity
and
benefits
of
booster
vaccination
against
coronavirus
2
severe
acute
respiratory
syndrome
(SARS-CoV-2)
Omicron
facilitate
clinical
decision-making
for
2019
disease
(COVID-19)
convalescents.
We
conducted
a
multicenter,
prospective
trial
(registration
number:
ChiCTR2100045810)
in
first
patients
with
COVID-19
from
28
January
2020
20
February
assess
long-term
durability
neutralizing
antibodies
live
BA.5
further
efficiency
safety
CoronaVac
convalescent
group.
A
total
96
convalescents
were
enrolled
this
study.
Neutralizing
antibody
titers
significantly
reduced
9–10
months.
dose-refreshing
an
titer
below
induced
by
4.84-fold.
Meanwhile,
abundance
naive
T
cells
increased
dramatically,
EMRA
EM
gradually
decreased
after
vaccination.
Activation-induced
cell
death
apoptosis-related
genes
elevated
all
T-cell
subtypes.
One-dose
was
effective
inducing
robust
response
SARS-CoV-2
low
titers.
However,
vaccine-mediated
consumption
regeneration
patterns
may
be
detrimental
antiviral
response.
IMPORTANCE
The
globally
dominant
variant
raises
possibility
repeat
infections
among
importance
multicenter
study
lies
its
evaluation
efficacy
Omicron.
findings
suggest
that
one-dose
also
highlights
potential
effects
on
due
patterns.
These
results
are
crucial
facilitating
informing
public
health
policies
regarding
vaccinations.
bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Март 4, 2024
Abstract
Several
effective
vaccines
for
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
have
been
developed
and
implemented
in
the
population.
However,
current
production
capacity
falls
short
of
meeting
global
demand.
Therefore,
it
is
crucial
to
further
develop
novel
vaccine
platforms
that
can
bridge
distribution
gap.
AVX/COVID-12
a
vector-based
utilizes
Newcastle
Disease
virus
(NDV)
present
SARS-CoV-2
spike
protein
immune
system.
This
study
analyses
antigenicity
candidate
by
examining
antibody
binding
T-cell
activation
individuals
infected
with
or
variants
concern
(VOCs),
as
well
healthy
volunteers
who
received
disease
2019
(COVID-19)
vaccinations.
Our
findings
indicate
effectively
binds
antibodies
activates
T-cells
3
doses
BNT162b2
AZ/ChAdOx-1-S
vaccines.
Furthermore,
stimulation
from
patients
recipients
resulted
their
proliferation
secretion
interferon-gamma
(IFN-γ)
both
CD4+
CD8+
T-cells.
In
conclusion,
vectored
demonstrates
ability
stimulate
robust
cellular
responses
recognized
primed
viruses
patients,
mRNA
These
results
support
inclusion
booster
vaccination
programs
aimed
at
addressing
COVID-19
caused
its
VOCs.
Research Square (Research Square),
Год журнала:
2024,
Номер
unknown
Опубликована: Март 22, 2024
AbstractPurpose
The
COVID-19
pandemic
has
been
marked
by
novel
viral
variants,
posing
challenges
to
global
public
health.
Recombination,
a
evolution
tool,
is
implicated
in
SARS-CoV-2's
ongoing
evolution.
The
XBB
recombinant
lineage,
known
for
evading
antibody-mediated
immunity,
exhibits
higher
transmissibility
without
increased
disease
severity.
We
investigated
the
prevalence
and
genomic
features
of
SARS-CoV-2-positive
cases
Rio
Grande
do
Sul
(RS),
Brazil.
Methods
We
sequenced
357
samples
from
epidemiological
weeks
(EW)
47/2022
17/2023,
included
389
publicly
available
sequences.
Clinical
data
were
obtained
DATASUS,
e-SUS,
SIVEP
GRIPE
(data
recording
systems
Brazilian
Ministry
Health)
Results
Of
these,
143
classified
as
586
other
Omicron
lineages.
BQ.1.1
lineage
was
most
frequent.
In
March
2023
(EW
10),
became
dominant,
accounting
83·3%
cases.
97·7%
XBB-infected
patients
successfully
recovered
infection,
with
low
mortality
rate.
Even
receiving
three
vaccine
doses
previously
infected,
59·5%
experienced
reinfection
XBB.
However,
interval
between
infection
last
dose
exceeded
year,
potentially
causing
antibody
decline.
addition,
we
identified
90
mutations
RS
circulating
XBB,
spread
throughout
genome,
notably
Spike
protein
region
associated
immune
resistance.
Conclusion
This
study
provides
insights
into
dynamics
impact
variant
becoming
predominant
first
time
state.
Continued
surveillance
SARS-CoV-2
crucial
effective
health
management.
bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Июль 3, 2024
ABSTRACT
Vaccines
have
historically
played
a
pivotal
role
in
controlling
epidemics.
Effective
vaccines
for
viruses
causing
significant
human
disease,
e.g
.,
Ebola,
Lassa
fever,
or
Crimean
Congo
hemorrhagic
fever
virus,
would
be
invaluable
to
public
health
strategies
and
counter-measure
development
missions.
Here,
we
propose
coverage
metrics
quantify
vaccine-induced
CD8
+
T
cell-mediated
immune
protection,
as
well
characterize
immuno-dominant
epitopes,
light
of
genetic
heterogeneity
viral
evolution.
Proof-of-principle
our
approach
methods
will
demonstrated
Ebola
SARS-CoV-2,
Burkholderia
pseudomallei
(vaccine)
proteins.
